DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
ETON logo

Eton Pharmaceuticals, Inc. Stock Price

NasdaqGM:ETON Community·US$1.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 42 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ETON Share Price Performance

US$58.83
41.41 (237.72%)
​
US$45.67
Fair Value
US$58.83
41.41 (237.72%)
28.8% overvalued intrinsic discount
US$45.67
Fair Value
Price US$58.83
AnalystConsensusTarget US$45.67
AnalystHighTarget US$76.00
AnalystLowTarget US$68.00
Mon, 29 Jun 26
Fair ValueUS$45.67
Share Pricen/a

ETON Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$45.67 28.8% overvalued intrinsic discount

Advances In Diagnosis And Orphan Drugs Will Open New Horizons

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$76 22.6% undervalued intrinsic discount

Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$68 13.5% undervalued intrinsic discount

Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ETON logo
Eton Pharmaceuticals
13.5% undervalued intrinsic discount
Updated

Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 9 Sep
Read Narrative
ETON logo
Eton Pharmaceuticals
22.6% undervalued intrinsic discount

Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 26 Aug
Read Narrative
ETON logo
Eton Pharmaceuticals
28.8% overvalued intrinsic discount

Advances In Diagnosis And Orphan Drugs Will Open New Horizons

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 29 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
ETON logo

ETON: Hemangioma Portfolio Momentum Will Drive Future Ultra Rare Upside

Fair Value: US$68 13.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
AnalystHighTarget
ETON logo

ETON: Pediatric Rare Disease Focus Will Drive Upside From Hemangioma Franchise Expansion

Fair Value: US$76 22.6% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
ETON logo

ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026

Fair Value: US$45.67 28.8% overvalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential with excellent balance sheet.

3 Risks
4 Rewards
View Full Analysis

Eton Pharmaceuticals, Inc. Key Details

US$105.6m

Revenue

US$40.7m

Cost of Revenue

US$64.8m

Gross Profit

US$52.2m

Other Expenses

US$12.7m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.44
61.41%
12.02%
59.9%
View Full Analysis

About ETON

Founded
2017
Employees
44
CEO
Sean Brynjelsen
WebsiteView website
www.etonpharma.com

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Recent ETON News & Updates

User avatar
Narrative Update • Sep 09

ETON: Hemangioma Portfolio Momentum Will Drive Future Ultra Rare Upside

Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $68 from $60, citing stronger contributions from Hemangeol, upgraded revenue and margin guidance, and added long-term pipeline expectations reflected in a higher future P/E assumption. Analyst Commentary Recent Street research on Eton Pharmaceuticals has focused on strong reported Q2 results, higher revenue and margin guidance, and increasing confidence in the commercial outlook for Hemangeol and other portfolio assets.
User avatar
Narrative Update • Aug 26

ETON: Pediatric Rare Disease Focus Will Drive Upside From Hemangioma Franchise Expansion

Analysts have raised their fair value estimate for Eton Pharmaceuticals from $62.00 to $76.00, citing higher modeled revenue growth and a higher future P/E multiple supported by recent price target increases following strong Q2 results and Hemangeol performance. Analyst Commentary Recent Street commentary on Eton Pharmaceuticals has been broadly constructive, with multiple bullish analysts lifting their price targets following Q2 results.

Recent updates

No updates

Eton Pharmaceuticals, Inc. Competitors

BIO logo

Bio-Rad Laboratories

Symbol: NYSE:BIO
Market cap: US$10.1b
PRAX logo

Praxis Precision Medicines

Symbol: NasdaqGS:PRAX
Market cap: US$9.8b
KYMR logo

Kymera Therapeutics

Symbol: NasdaqGM:KYMR
Market cap: US$9.6b
RGEN logo

Repligen

Symbol: NasdaqGS:RGEN
Market cap: US$9.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide